| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Rat |
| Target | Nerve growth factor (NGF) |
| Clinical data | |
| Trade names | Solensia |
| License data |
|
| Routes of administration | Subcutaneous |
| ATCvet code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
| KEGG | |
Frunevetmab, sold under the brand name Solensia, is a monoclonal antibody used to treat pain associated with osteoarthritis in cats.[3] It is the first monoclonal antibody drug approved by the US Food and Drug Administration for animal use.[3] Frunevetmab is the international nonproprietary name.[5]
Frunevetmab is a cat-specific monoclonal antibody (a type of protein) designed to recognize and attach to a protein called nerve growth factor that is involved in the regulation of pain.[3] When frunevetmab binds to nerve growth factor, it prevents the pain signal from reaching the brain.[3]
Frunevetmab is indicated for the alleviation of pain associated with osteoarthritis in cats.[3][4]
The most common side effects seen in cats include vomiting, diarrhea, injection site pain, scabbing on the head and neck, dermatitis, and pruritus (itchy skin).[3]
In February 2021, frunevetmab was approved for medical use in the European Union.[4]
In January 2022, frunevetmab was approved for medical use in the United States.[3][6]
Development as a potential drug for humans was stopped due to risk concerns over worsening osteoarthritis.[7]
This article incorporates text from this source, which is in the public domain.
This article incorporates public domain material from the United States Department of Health and Human Services
 | This veterinary medicine–related article is a stub. You can help Wikipedia by expanding it. |
